Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Dec 2, 2020
Distillery Therapeutics
SQSTM1, INSR identified as targets in sepsis
DISEASE CATEGORY: Infectious disease
INDICATION: Sepsis Inhibiting the scaffold protein SQSTM1 or its extracellular receptor INSR could treat bacterial sepsis. Among 40 patients with bacterial
INDICATION: Sepsis Inhibiting the scaffold protein SQSTM1 or its extracellular receptor INSR could treat bacterial sepsis. Among 40 patients with bacterial
BioCentury | Jun 27, 2019
Distillery Therapeutics
An insulin-conjugated dual SLC2A1/SLC2A4 inhibitor for diabetes
BioCentury | Jul 28, 2017
Clinical News
Adocia begins head-to-head trial of BioChaperone Lispro vs. Fiasp and Novolog
BioCentury | Jul 7, 2017
Clinical News
Novo Nordisk reports additional Phase III DEVOTE data of Tresiba on CV outcomes
Items per page:
1 - 10 of 141